Delving into the Latest Updates on Altesa BioSciences, Inc. with Synapse

A Trial in Participants With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus Challenge

Vapendavir (VPV) is a drug being developed to treat human rhinovirus (RV) infection, one virus responsible for the common cold. Vapendavir prevents the virus from entering cells and making more infectious copies of itself. A study is being planned to investigate VPV in patients with chronic obstructive pulmonary disease (COPD, a lung disease making it difficult to breathe) who develop a rhinoviral infection; however, VPV has not been approved for use in treating any indication (disease) by the FDA or any other global regulatory agency. Therefore, VPV is considered investigational, and the study doctor is conducting this investigational research study. Safety will be monitored throughout the entire study.

开始日期2023-11-20

申办/合作机构

Altesa BioSciences, Inc.

[+1]

NCT05962645 / Completed临床1期

A Phase 1 Study to Confirm the Single- and Multiple-dose Pharmacokinetics and to Evaluate Food Effect of Vapendavir in Healthy Participants and Participants With COPD

Vapendavir (VPV) is potent virostatic antiviral agent active against all known enterovirus species. VPV binds to the viral capsid, thereby inhibiting viral attachment to the target cell and, independently, preventing release of viral RNA (ribonucleic acid) into the cell. Alt VPV-101 is meant to investigate vapendavir in patients with chronic obstructive pulmonary disease (COPD) who develop a rhinoviral infection. This is a Phase 1, open-label, unblinded study. The primary objective of this study is to characterize single and multiple dose (plus a loading dose) plasma PK profiles of VPV in healthy participants (Group A) and participants with COPD (Group B). Group A is an open-label, 2-sequence, and up to a 3-period, cross-over study to assess the single-dose PK parameters and safety of VPV. Healthy participants may opt to participate in only the first 2 periods, all 3 periods or BID dosing, but it is preferred that participants complete all 3 periods. Group B is an open-label, multi-dose investigation of VPV PK parameters and safety in participants with COPD. Post-dose, follow up will continue for a minimum of 14 days and a maximum of 30 days, depending on which Group the participant is in and which periods said participant completes. There is a target for up to 24 adult participants comprised of healthy participants and participants with COPD.

开始日期2023-05-19

申办/合作机构

Altesa BioSciences, Inc.

100 项与 Altesa BioSciences, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Altesa BioSciences, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 Altesa BioSciences, Inc. 相关的新闻（医药）

2023-04-11

·Business Wire

Surescripts Launches Season 2 of its Award-Winning Podcast

ARLINGTON, Va.--( BUSINESS WIRE )--Surescripts, the nation’s leading health information network, has launched the second season of its award-winning podcast, There’s a Better Way: Smart Talk on Healthcare and Technology . Listen to There’s a Better Way: Season 2 trailer . Surescripts Chief Marketing Officer Melanie Marcus, returns as host with a whole new set of guests who are leading change and improving healthcare with a diverse set of experiences and perspectives, including, among others: Micky Tripathi, National Coordinator for Health Information Technology at the U.S. Department of Health and Human Services Rina Shah, Pharm.D, Global Vice President, Pharmacy of the Future & Healthcare Strategy Segment at Walgreens Brett Giroir M.D., Chief Executive Officer, Altesa BioSciences, Inc. “The challenges facing healthcare run the gamut. Yet there’s one thing all of our podcast guests have in common -- stories of inspiration, innovation, partnership and hope for the future of healthcare,” said Marcus. “We can’t wait to share how these leaders are tackling growing challenges like how to best support the evolving role of pharmacists, improve access to clinical care for patients when alarming numbers of clinicians leave their practice and how to advance interoperability to bring relief to clinicians experiencing burnout while better informing patient care.” Surescripts introduced There’s a Better Way: Smart Talk on Healthcare and Technology in July 2022, with visionary guests such as Mariann Yeager, Chief Executive Officer of the Sequoia Project, Lee Barrett, Chief Executive Officer of the Electronic Healthcare Network Accreditation Commission (EHNAC), Dr. Nele Jessel, Chief Medical Officer of athenahealth, Michele Belcher, former president of the National Community Pharmacists Association, Sam Lambson, Vice President of Interoperability for Oracle Cerner, and Colleen Lindholz, President of Kroger Health. Its first season was recognized by the Association of Marketing and Communication Professionals with the 2022 Gold MarCom Award . Catch up on the first season and tune in to season two available now on all major apps. About Surescripts Our purpose is to serve the nation through simpler, trusted health intelligence sharing, in order to increase patient safety, lower costs and ensure quality care. At Surescripts, we align healthcare organizations across the nation and give healthcare professionals the trusted insights they need to serve patients. We convene the Surescripts Network Alliance® to enhance prescribing, better inform care decisions and advance healthcare as a whole. Together, we’re making interoperability an everyday reality, making it simpler to choose medications patients can afford and adhere to, and getting specialty medications to patients more efficiently. Visit us at surescripts.com and follow us at twitter.com/surescripts .

临床2期

100 项与 Altesa BioSciences, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Altesa BioSciences, Inc. 相关的转化医学

登录后查看更多信息